In Latin America, Grünenthal is further strengthening the business in these fast-growth emerging markets with selected acquisitions and licensing deals. Following the successful acquisition and integration of the Brazilian company Selfarma in 2011, Grünenthal announced in June 2012 an exclusive agreement with US-based Horizon Pharma for the commercialization of DUEXIS ® in Latin America. The company's current leading market position in Latin America is mainly based on a strong portfolio in pain, Grünenthal's global core competence along with strong regional products.
More information about Grünenthal: http://www.grunenthal.com
Additional information for editorial offices: Oscar Ferenczi ' s CV can be downloaded on our website: http://ots.de/gUNiG
Contact: Frank Schönrock, Vice President Corporate Affairs Tel.: +49-241-569-1568, Fax: +49-241-569-3539, email@example.comGrünenthal GmbH, 52099 Aachen, Deutschland, http://www.grunenthal.com SOURCE Grunenthal GmbH